EMPEROR-Preserved: Empagliflozin and Outcomes in Heart Failure with a Preserved Ejection Fraction and Chronic Kidney Disease

被引：0
|
作者：
Wanner, Christoph [1 ]
机构：
[1] Univ Hosp Wurzburg, Dept Internal Med 1, Wurzburg, Germany
来源：
INTERNIST | 2022年 / 63卷 / SUPPL 3期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PS083
引用
收藏
页码：349 / 349
页数：1
相关论文
共 50 条
  • [21] Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
    Pocock, Stuart J.
    Ferreira, Joao Pedro
    Packer, Milton
    Zannad, Faiez
    Filippatos, Gerasimos
    Kondo, Toru
    McMurray, John J., V
    Solomon, Scott D.
    Januzzi, James L.
    Iwata, Tomoko
    Salsali, Afshin
    Butler, Javed
    Anker, Stefan D.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (10) : 1869 - 1878
  • [22] Plain language summary of the EMPEROR-Preserved study looking at the effect of empagliflozin in patients with heart failure with preserved ejection fraction, with and without diabetes
    Butler, Javed
    Filippatos, Gerasimos
    [J]. FUTURE CARDIOLOGY, 2023, 19 (15) : 723 - 733
  • [23] Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
    Stefan D. Anker
    Javed Butler
    Muhammad Shariq Usman
    Gerasimos Filippatos
    João Pedro Ferreira
    Edimar Bocchi
    Michael Böhm
    Hans Pieter Brunner-La Rocca
    Dong-Ju Choi
    Vijay Chopra
    Eduardo Chuquiure
    Nadia Giannetti
    Juan Esteban Gomez-Mesa
    Stefan Janssens
    James L. Januzzi
    José R. González-Juanatey
    Bela Merkely
    Stephen J. Nicholls
    Sergio V. Perrone
    Ileana L. Piña
    Piotr Ponikowski
    Michele Senni
    David Sim
    Jindrich Spinar
    Iain Squire
    Stefano Taddei
    Hiroyuki Tsutsui
    Subodh Verma
    Dragos Vinereanu
    Jian Zhang
    Tomoko Iwata
    Janet M. Schnee
    Martina Brueckmann
    Stuart J. Pocock
    Faiez Zannad
    [J]. Nature Medicine, 2022, 28 : 2512 - 2520
  • [24] Effects of empagliflozin in patients with heart failure and preserved ejection fraction according to baseline diuretic use: results from the EMPEROR-Preserved trial
    Butler, J.
    [J]. EUROPEAN HEART JOURNAL, 2022, 43 : 982 - 982
  • [25] Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
    Anker, Stefan D.
    Butler, Javed
    Usman, Muhammad Shariq
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Bocchi, Edimar
    Bohm, Michael
    Brunner-La Rocca, Hans Pieter
    Choi, Dong-Ju
    Chopra, Vijay
    Chuquiure, Eduardo
    Giannetti, Nadia
    Gomez-Mesa, Juan Esteban
    Janssens, Stefan
    Januzzi, James L.
    Gonzalez-Juanatey, Jose R.
    Merkely, Bela
    Nicholls, Stephen J.
    Perrone, Sergio V.
    Pina, Ileana L.
    Ponikowski, Piotr
    Senni, Michele
    Sim, David
    Spinar, Jindrich
    Squire, Iain
    Taddei, Stefano
    Tsutsui, Hiroyuki
    Verma, Subodh
    Vinereanu, Dragos
    Zhang, Jian
    Iwata, Tomoko
    Schnee, Janet M.
    Brueckmann, Martina
    Pocock, Stuart J.
    Zannad, Faiez
    [J]. NATURE MEDICINE, 2022, 28 (12) : 2512 - +
  • [26] Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction A Post Hoc Analysis of the EMPEROR-Preserved Trial
    Butler, Javed
    Usman, Muhammad Shariq
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Boehm, Michael
    Brueckmann, Martina
    Januzzi, James L.
    Kaul, Sanjay
    Pina, Ileana L.
    Ponikowski, Piotr
    Senni, Michele
    Sumin, Mikhail
    Verma, Subodh
    Zaremba-Pechmann, Liliana
    Pocock, Stuart J.
    Packer, Milton
    Anker, Stefan
    [J]. JAMA CARDIOLOGY, 2023, 8 (07) : 640 - 649
  • [27] Heart failure with a preserved ejection fraction and the EMPEROR-Preserved Trial: a review of how we got here
    de Abreu, Tiago Tribolet
    [J]. HEART FAILURE REVIEWS, 2022, 27 (06) : 2077 - 2082
  • [28] Heart failure with a preserved ejection fraction and the EMPEROR-Preserved Trial: a review of how we got here
    Tiago Tribolet de Abreu
    [J]. Heart Failure Reviews, 2022, 27 : 2077 - 2082
  • [29] Empagliflozin in Heart Failure with a Preserved Ejection Fraction
    不详
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (21):
  • [30] Empagliflozin in Heart Failure with a Preserved Ejection Fraction
    Anker, Stefan D.
    Butler, Javed
    Filippatos, Gerasimos
    Ferreira, Joao P.
    Bocchi, Edimar
    Boehm, Michael
    Brunner-La Rocca, Hans-Peter
    Choi, Dong-Ju
    Chopra, Vijay
    Chuquiure-Valenzuela, Eduardo
    Giannetti, Nadia
    Gomez-Mesa, Juan Esteban
    Janssens, Stefan
    Januzzi, James L.
    Gonzalez-Juanatey, Jose R.
    Merkely, Bela
    Nicholls, Stephen J.
    Perrone, Sergio V.
    Pina, Ileana L.
    Ponikowski, Piotr
    Senni, Michele
    Sim, David
    Spinar, Jindrich
    Squire, Iain
    Taddei, Stefano
    Tsutsui, Hiroyuki
    Verma, Subodh
    Vinereanu, Dragos
    Zhang, Jian
    Carson, Peter
    Lam, Carolyn Su Ping
    Marx, Nikolaus
    Zeller, Cordula
    Sattar, Naveed
    Jamal, Waheed
    Schnaidt, Sven
    Schnee, Janet M.
    Brueckmann, Martina
    Pocock, Stuart J.
    Zannad, Faiez
    Packer, Milton
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16): : 1451 - 1461
12345